A Phase 2, Non-Randomized, Open-Label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Trial Profile

A Phase 2, Non-Randomized, Open-Label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Ramucirumab (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 14 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 23 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
    • 14 Jul 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top